Fingerprint
Dive into the research topics of 'Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Clare Robertson, Shona Fielding, Andrew Walker, Daniel Kopasker, Thenmalar Vadiveloo, Paul Manson, Gillian Price, Miriam Brazzelli, Graham Scotland
Research output: Book/Report › Commissioned Report